210 related articles for article (PubMed ID: 20430179)
1. Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience.
Said T; Al-Otaibi T; Al-Wahaib S; Francis I; Nair MP; Halim MA; El-Sayed A; Nampoory MR
Transplant Proc; 2010 Apr; 42(3):814-6. PubMed ID: 20430179
[TBL] [Abstract][Full Text] [Related]
2. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.
Caires RA; Marques ID; Repizo LP; Sato VA; Carmo LP; Machado DJ; de Paula FJ; Nahas WC; David-Neto E
Transplant Proc; 2012 Oct; 44(8):2388-90. PubMed ID: 23026601
[TBL] [Abstract][Full Text] [Related]
3. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections.
Artz MA; Steenbergen EJ; Hoitsma AJ; Monnens LA; Wetzels JF
Transplantation; 2003 Sep; 76(5):821-6. PubMed ID: 14501861
[TBL] [Abstract][Full Text] [Related]
4. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
[TBL] [Abstract][Full Text] [Related]
5. Postrenal transplant hemolytic uremic syndrome/thrombotic microangiopathy: Ahmedabad experience.
Goplani KR; Vanikar AV; Shah PR; Gumber M; Feroz A; Patel HV; Kasat P; Falodia J; Saboo D; Kaswaan K; Geerish MS; Pandya T; Trivedi HL
Transplant Proc; 2008 May; 40(4):1114-6. PubMed ID: 18555127
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of hemolytic uremic syndrome after liver-kidney transplantation.
Gatti S; Arru M; Reggiani P; Como G; Rossi F; Fassati LR; Ponticelli C
J Nephrol; 2003; 16(4):586-90. PubMed ID: 14696763
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.
Bren A; Pajek J; Grego K; Buturovic J; Ponikvar R; Lindic J; Knap B; Vizjak A; Ferluga D; Kandus A
Transplant Proc; 2005 May; 37(4):1889-91. PubMed ID: 15919494
[TBL] [Abstract][Full Text] [Related]
9. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
[TBL] [Abstract][Full Text] [Related]
10. A case of late onset cyclosporine-induced hemolytic uremic syndrome resulting in renal graft loss.
Katafuchi R; Saito S; Ikeda K; Hirano T; Yanase T; Nakashima K; Fujimi S
Clin Transplant; 1999; 13 Suppl 1():54-8. PubMed ID: 10751058
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus-associated hemolytic uremic syndrome: a case analysis.
Lin CC; King KL; Chao YW; Yang AH; Chang CF; Yang WC
J Nephrol; 2003; 16(4):580-5. PubMed ID: 14696762
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
13. Graft failure due to hemolytic uremic syndrome recurrence.
Iaria G; Iorio B; Anselmo A; De Luca L; Tariciotti L; Ielpo B; Muzi F; Lucchesi C; D'Andria D; Orlando G; Del Poeta G; Poggi E; Piazza A; Tisone G
Transplant Proc; 2006 May; 38(4):1020-1. PubMed ID: 16757250
[TBL] [Abstract][Full Text] [Related]
14. [Hemolytic-uremic syndrome following kidney transplantation: prognostic factors].
Candinas D; Keusch G; Schlumpf R; Burger HR; Gmür J; Largiadèr F
Schweiz Med Wochenschr; 1994 Oct; 124(41):1789-99. PubMed ID: 7973505
[TBL] [Abstract][Full Text] [Related]
15. [A case of hemolytic uremic syndrome after cadaveric renal transplantation].
Nagano T; Ikegami M; Matsuda H; Akiyama T; Kurita T
Hinyokika Kiyo; 1996 Jan; 42(1):59-61. PubMed ID: 8686587
[TBL] [Abstract][Full Text] [Related]
16. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
17. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
Kandaswamy R; Humar A; Casingal V; Gillingham KJ; Ibrahim H; Matas AJ
Transplantation; 2007 Mar; 83(6):722-6. PubMed ID: 17414704
[TBL] [Abstract][Full Text] [Related]
18. Atypical calcineurin inhibitor-induced haemolytic uremic syndrome after liver transplantation.
Furmańczyk A; Komuda-Leszek E; Durlik M
Ann Transplant; 2009; 14(4):47-51. PubMed ID: 20009155
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
